Last reviewed · How we verify
ALKS 2680 Dose 1
ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms.
ALKS 2680 is a muscarinic M1 receptor partial agonist designed to enhance cognitive function and treat psychiatric symptoms. Used for Cognitive impairment associated with schizophrenia, Negative symptoms of schizophrenia.
At a glance
| Generic name | ALKS 2680 Dose 1 |
|---|---|
| Also known as | Alixorexton |
| Sponsor | Alkermes, Inc. |
| Drug class | Muscarinic M1 receptor partial agonist |
| Target | M1 muscarinic acetylcholine receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | Phase 3 |
Mechanism of action
The drug selectively targets M1 muscarinic receptors in the brain, which are involved in cognition, attention, and memory. By acting as a partial agonist, it modulates cholinergic neurotransmission to improve cognitive deficits associated with schizophrenia and other neuropsychiatric conditions. This mechanism differs from typical antipsychotics by focusing on cognitive enhancement rather than dopamine antagonism alone.
Approved indications
- Cognitive impairment associated with schizophrenia
- Negative symptoms of schizophrenia
Common side effects
- Nausea
- Headache
- Diarrhea
- Dizziness
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1 (PHASE3)
- A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ALKS 2680 Dose 1 CI brief — competitive landscape report
- ALKS 2680 Dose 1 updates RSS · CI watch RSS
- Alkermes, Inc. portfolio CI